Results 11 to 20 of about 28,600 (213)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

BMC Psychiatry, 2012
Background To treat acute schizophrenia, a long-acting injectable antipsychotic needs a rapid onset of action and therapeutic profile similar to that of oral agents.
Detke Holland C, Zhao Fangyi, Witte Michael M   +2 more
doaj   +1 more source

Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice [PDF]

Iranian Journal of Basic Medical Sciences, 2018
Objective(s): Weight gain and metabolic disturbances such as dyslipidemia, are frequent side effects of second-generation antipsychotics, including olanzapine. This study examined the metabolic effects of chronic olanzapine exposure.
Po-Hsun Hou, Geng-Ruei Chang, Chin-Pin Chen, Yen-Ling Lin, I-Shuan Chao, Ting-Ting Shen, Frank Mao   +6 more
doaj   +1 more source

Olanzapine induced tardive dyskinesia

Medical Journal of Dr. D.Y. Patil University, 2014
Olanzapine is considered to have significantly less risk of tardive dyskinesia (TD) compared to first generation antipsychotics. We describe two patients who developed TD after prolonged use of olanzapine.
Rudraprosad Chakraborty, Arunima Chatterjee, Suprakash Chaudhury   +2 more
doaj   +1 more source

Olanzapine-induced hiccups： a case report

Sichuan jingshen weisheng, 2021
The case report aims to raise the concern of clinicians about hiccups as an adverse reaction in olanzapine treatment. A 47-year-old male patient with epileptic mental disorder appeared symptoms of persistent hiccups on the fourth day of treatment with ...
Sun Zhenxiao, Xu Chunmei, Zhao Lin
doaj   +1 more source

Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes

eLife, 2020
Second-generation antipsychotics are widely used to medicate patients with schizophrenia, but may cause metabolic side effects such as diabetes, which has been considered to result from obesity-associated insulin resistance.
Satoshi Ninagawa, Seiichiro Tada, Masaki Okumura, Kenta Inoguchi, Misaki Kinoshita, Shingo Kanemura, Koshi Imami, Hajime Umezawa, Tokiro Ishikawa, Robert B Mackin, Seiji Torii, Yasushi Ishihama, Kenji Inaba, Takayuki Anazawa, Takahiko Nagamine, Kazutoshi Mori   +15 more
doaj   +1 more source

Teratogenicity with Olanzapine

Indian Journal of Psychological Medicine, 2014
Olanzapine, a 2(nd) generation antipsychotic, is in use in the clinical practice for nearly a decade and a half now. It is classified as a category C drug with very few reports of its toxic effects on the fetus. In general, the risk benefit analysis warrants its use in pregnancy.
Sathya Prakash, Rakesh Kumar Chadda
openaire   +4 more sources

Olanzapine pamoate use for schizophrenia: Retrospective records based study from a tertiary care hospital

Indian Journal of Psychological Medicine, 2020
Background: Little is known from India about the experience of using olanzapine long-acting antipsychotic injectables (LAI). In this background, this study aimed to evaluate the clinical profile of patients suffering from schizophrenia who were ...
Sandeep Grover, Himanshu Singla, Subho Chakrabarti, Ajit Avasthi   +3 more
doaj   +1 more source

Hematological safety of olanzapine

Psychiatria i Psychologia Kliniczna, 2016
Olanzapine is an atypical antipsychotic medication, previously expected to be safe in terms of hematological side effects and considered an alternative choice to clozapine in patients who develop hematotoxicities.
Asem A Alageel, Eisha M Gaffas
doaj   +1 more source

Metformin and berberine prevent olanzapine-induced weight gain in rats. [PDF]

PLoS ONE, 2014
Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain.
Yueshan Hu, Alan J Young, Erik A Ehli, Dustin Nowotny, Paige S Davies, Elizabeth A Droke, Timothy J Soundy, Gareth E Davies   +7 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source